Hospital
White Memorial Medical Center
White Memorial Medical Center was paid $62.37M by Medicaid between Jan 2018 and Dec 2024, across 461 billing codes. Its largest line is 0450, Emergency room services — 16% of everything it billed.
33Billing provider infoWHITE MEMORIAL MEDICAL CENTER
LOS ANGELES, CA 90033
LOS ANGELES, CA 90033
33aNPI1215927470assigned 10/27/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$62.37M
24GClaims1,869,151
24DCodes billed461
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#47 of 410
Median peer was paid$6.90M
This provider vs. median9.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 245,174 | $7.80M | |
| 2019 | 223,193 | $10.76M | |
| 2020 | 165,129 | $6.31M | |
| 2021 | 203,335 | $7.07M | |
| 2022 | 266,111 | $9.83M | |
| 2023 | 372,432 | $10.56M | |
| 2024incomplete | 393,777 | $10.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 16% | 151,697 | 138,382 | $9.69M |
| 0206 | 5.9% | 1,441 | 1,372 | $3.68M | |
| 0121 | 5.8% | 1,355 | 1,279 | $3.62M | |
| 0360 | 5.6% | 21,283 | 16,286 | $3.48M | |
| 99199 | Unlisted special service, procedure or report | 4.6% | 19,441 | 17,481 | $2.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.7% | 7,832 | 7,365 | $1.69M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.1% | 11,917 | 10,892 | $1.34M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.9% | 3,866 | 3,653 | $1.17M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 5,164 | 5,084 | $1.16M |
| 80053 | Comprehensive metabolic panel | 1.8% | 95,506 | 87,506 | $1.12M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.6% | 12,957 | 11,049 | $987K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 9,401 | 9,191 | $939K |
449 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.4% | 4,710 | $879K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 46,271 | $808K |
| Z7502 | 1.3% | 21,456 | $800K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 6,242 | $656K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.0% | 15,272 | $628K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 102,266 | $616K |
| 0762 | <1% | 3,017 | $584K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 16,640 | $573K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,731 | $568K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 24,900 | $567K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 12,962 | $563K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,183 | $535K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 293 | $525K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 439 | $480K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 2,293 | $441K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,720 | $440K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 2,569 | $432K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 5,312 | $429K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 11,740 | $421K |
| 71045 | Radiologic examination, chest; single view | <1% | 39,711 | $415K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 5,785 | $390K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,661 | $380K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 13,106 | $354K |
| 11043 | <1% | 3,779 | $354K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,467 | $353K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,444 | $337K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,032 | $322K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,818 | $316K |
| 0510 | <1% | 16,431 | $309K | |
| 0710 | <1% | 10,254 | $305K | |
| J3490 | Unclassified drugs | <1% | 57,555 | $304K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,444 | $284K |
| 0278 | <1% | 397 | $273K | |
| 84484 | <1% | 33,320 | $272K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,422 | $270K |
| G0378 | Hospital observation service, per hour | <1% | 567 | $258K |
| Z9725 | <1% | 8,558 | $257K | |
| 0160 | <1% | 433 | $255K | |
| 0123 | <1% | 103 | $253K | |
| 93798 | <1% | 5,618 | $250K | |
| 0729 | <1% | 9,718 | $247K | |
| 0250 | <1% | 28,909 | $245K | |
| Z4300 | <1% | 2,357 | $243K | |
| 97139 | <1% | 15,306 | $242K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12,425 | $236K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,816 | $221K |
| 81001 | <1% | 75,078 | $218K | |
| 93970 | <1% | 1,474 | $217K | |
| 0272 | <1% | 2,048 | $210K | |
| 81025 | <1% | 42,887 | $210K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,110 | $208K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 8,258 | $192K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,489 | $191K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 30,017 | $188K |
| 83690 | <1% | 31,778 | $185K | |
| 93971 | <1% | 2,222 | $181K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,878 | $177K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,530 | $175K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 950 | $174K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 15,938 | $172K |
| 83880 | <1% | 8,650 | $169K | |
| 0270 | <1% | 33,133 | $161K | |
| 94060 | <1% | 687 | $161K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,114 | $157K |
| 93017 | <1% | 1,171 | $148K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 873 | $140K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 19,395 | $134K |
| J2704 | Injection, propofol, 10 mg | <1% | 7,169 | $132K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,990 | $132K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,809 | $132K |
| 0122 | <1% | 130 | $129K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,126 | $129K |
| 59025 | Fetal non-stress test | <1% | 8,779 | $127K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,367 | $125K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 868 | $116K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 819 | $115K |
| 87040 | <1% | 12,245 | $113K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,493 | $113K |
| 76830 | Ultrasound, transvaginal | <1% | 2,269 | $111K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,173 | $111K |
| 97750 | <1% | 3,561 | $110K | |
| 88342 | <1% | 6,557 | $107K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,636 | $105K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,577 | $103K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,290 | $103K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 542 | $102K |
| 0300 | <1% | 3,901 | $98K | |
| Q4133 | Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure) | <1% | 177 | $95K |
| 72100 | <1% | 3,127 | $94K | |
| 73630 | <1% | 3,990 | $90K | |
| 0259 | <1% | 13,785 | $90K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,013 | $89K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,102 | $89K |
| 84702 | <1% | 7,504 | $84K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,720 | $81K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,133 | $80K |
| 97010 | <1% | 5,094 | $78K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 381 | $77K |
| 97799 | <1% | 4,778 | $75K | |
| 97116 | <1% | 5,723 | $71K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,200 | $71K |
| 73610 | <1% | 3,311 | $69K | |
| 85730 | <1% | 14,285 | $67K | |
| 83605 | <1% | 8,349 | $67K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 2,711 | $66K |
| 90715 | <1% | 2,163 | $64K | |
| 99070 | <1% | 30,644 | $63K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 444 | $62K |
| 73030 | <1% | 3,354 | $61K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,386 | $61K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,447 | $60K |
| 70496 | <1% | 390 | $59K | |
| 0760 | <1% | 3,397 | $59K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 282 | $59K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,351 | $58K |
| 70498 | <1% | 404 | $56K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,687 | $55K |
| 73130 | <1% | 2,654 | $55K | |
| 99221 | <1% | 1,954 | $54K | |
| 87186 | <1% | 8,029 | $54K | |
| 85610 | <1% | 15,349 | $52K | |
| 82948 | <1% | 12,025 | $51K | |
| Z4303 | <1% | 1,156 | $50K | |
| 94729 | <1% | 579 | $48K | |
| 82962 | <1% | 12,417 | $48K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 1,478 | $47K |
| 94726 | <1% | 629 | $45K | |
| 87641 | <1% | 2,288 | $45K | |
| 72040 | <1% | 2,041 | $45K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 138 | $43K |
| 73110 | <1% | 1,603 | $42K | |
| 74018 | <1% | 2,357 | $42K | |
| 0001A | <1% | 1,160 | $41K | |
| 86901 | <1% | 9,316 | $41K | |
| 00731 | <1% | 469 | $41K | |
| 15275 | <1% | 246 | $41K | |
| 73562 | <1% | 1,706 | $41K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 8,223 | $40K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,255 | $40K |
| G6002 | Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | <1% | 1,268 | $40K |
| 92523 | <1% | 669 | $39K | |
| Z7500 | <1% | 1,133 | $39K | |
| 97161 | <1% | 1,256 | $38K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,470 | $37K |
| 86900 | <1% | 7,749 | $37K | |
| C1769 | Guide wire | <1% | 154 | $36K |
| 70486 | <1% | 376 | $35K | |
| 76857 | <1% | 1,579 | $35K | |
| 87077 | <1% | 5,897 | $34K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 5,171 | $32K |
| 76775 | <1% | 754 | $31K | |
| 72141 | <1% | 181 | $30K | |
| Z4304 | <1% | 378 | $29K | |
| 76870 | <1% | 727 | $29K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,854 | $29K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,229 | $29K |
| 97165 | <1% | 867 | $29K | |
| 01961 | <1% | 183 | $29K | |
| 76641 | <1% | 487 | $28K | |
| 47562 | <1% | 26 | $28K | |
| 93923 | <1% | 205 | $28K | |
| 76642 | <1% | 695 | $27K | |
| 87081 | <1% | 3,740 | $27K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,191 | $26K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 84 | $26K |
| 93350 | <1% | 289 | $26K | |
| 73560 | <1% | 1,673 | $26K | |
| 97014 | <1% | 1,794 | $25K | |
| 88313 | <1% | 2,316 | $24K | |
| 71250 | <1% | 265 | $24K | |
| 87088 | <1% | 4,163 | $23K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,768 | $23K |
| Z4301 | <1% | 952 | $23K | |
| 73564 | <1% | 939 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,630 | $23K |
| 0002A | <1% | 625 | $22K | |
| 83735 | <1% | 5,174 | $22K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,902 | $22K |
| 72131 | <1% | 270 | $22K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 249 | $21K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,483 | $21K |
| 73590 | <1% | 1,170 | $21K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,361 | $21K |
| 92522 | <1% | 344 | $21K | |
| 00813 | <1% | 193 | $20K | |
| 77065 | Tomosynthesis, mammo | <1% | 304 | $20K |
| 77427 | <1% | 196 | $20K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,838 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,539 | $19K |
| 0761 | <1% | 1,186 | $19K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 116 | $18K |
| 97755 | <1% | 493 | $18K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,209 | $18K |
| 86850 | <1% | 2,972 | $18K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 425 | $17K |
| 86300 | <1% | 1,245 | $17K | |
| 49083 | <1% | 31 | $17K | |
| 99152 | <1% | 703 | $17K | |
| 73502 | <1% | 687 | $17K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,558 | $16K |
| 77336 | <1% | 331 | $16K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,702 | $16K |
| 81003 | <1% | 6,817 | $16K | |
| 92587 | <1% | 432 | $15K | |
| 88304 | <1% | 1,987 | $15K | |
| 0420 | <1% | 600 | $15K | |
| 80061 | Lipid panel | <1% | 3,288 | $15K |
| 73080 | <1% | 690 | $15K | |
| 29125 | <1% | 394 | $14K | |
| 85027 | <1% | 3,096 | $14K | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 29 | $14K |
| 73140 | <1% | 807 | $14K | |
| 80143 | <1% | 794 | $13K | |
| 93458 | <1% | 15 | $12K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 69 | $12K |
| 92611 | <1% | 151 | $12K | |
| 97802 | <1% | 143 | $12K | |
| 82378 | <1% | 537 | $12K | |
| C1781 | Mesh (implantable) | <1% | 34 | $11K |
| A0429 | Emergency ambulance ride, basic life support | <1% | 133 | $11K |
| Z7610 | <1% | 9,713 | $11K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,315 | $11K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 306 | $11K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,885 | $11K |
| 87807 | <1% | 1,508 | $11K | |
| 96367 | <1% | 390 | $11K | |
| 84100 | <1% | 2,965 | $10K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 147 | $10K |
| 97533 | <1% | 1,391 | $10K | |
| 85379 | <1% | 1,453 | $10K | |
| 84703 | <1% | 1,974 | $10K | |
| 80179 | <1% | 732 | $10K | |
| 74174 | <1% | 45 | $10K | |
| 80076 | <1% | 2,284 | $10K | |
| 82010 | <1% | 1,774 | $10K | |
| 87070 | <1% | 1,004 | $9K | |
| V2632 | Posterior chamber intraocular lens | <1% | 97 | $9K |
| 71100 | <1% | 456 | $9K | |
| 86140 | <1% | 2,832 | $9K | |
| 93880 | <1% | 118 | $9K | |
| 76801 | <1% | 216 | $9K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 815 | $8K |
| 12001 | <1% | 208 | $8K | |
| 77014 | <1% | 358 | $8K | |
| 85007 | <1% | 3,059 | $8K | |
| Z9727 | <1% | 256 | $8K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,060 | $8K |
| 92557 | <1% | 164 | $8K | |
| 73090 | <1% | 499 | $7K | |
| 82550 | <1% | 1,614 | $7K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 650 | $7K |
| 97162 | <1% | 272 | $7K | |
| 0370 | <1% | 1,286 | $7K | |
| 84145 | <1% | 423 | $7K | |
| 88307 | <1% | 362 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 883 | $7K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,223 | $7K |
| 88341 | <1% | 126 | $7K | |
| 77334 | <1% | 71 | $7K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 338 | $6K |
| 84480 | <1% | 403 | $6K | |
| 0252 | <1% | 1,205 | $6K | |
| 72170 | <1% | 419 | $6K | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 80 | $6K |
| 0636 | <1% | 1,281 | $6K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 938 | $6K |
| 82805 | <1% | 130 | $6K | |
| 76000 | <1% | 350 | $6K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,888 | $6K |
| 84439 | <1% | 1,084 | $6K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 340 | $6K |
| 11721 | <1% | 82 | $6K | |
| 85651 | <1% | 2,307 | $6K | |
| 92570 | <1% | 145 | $5K | |
| 97803 | <1% | 113 | $5K | |
| 72110 | <1% | 199 | $5K | |
| 10060 | <1% | 337 | $5K | |
| 00811 | <1% | 76 | $5K | |
| 92521 | <1% | 63 | $5K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 492 | $5K |
| 0440 | <1% | 156 | $5K | |
| 97163 | <1% | 98 | $5K | |
| 0258 | <1% | 3,553 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,394 | $4K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 204 | $4K |
| 87400 | <1% | 568 | $4K | |
| 74230 | <1% | 65 | $4K | |
| 0301 | <1% | 3,297 | $4K | |
| 94664 | <1% | 585 | $4K | |
| 12011 | <1% | 109 | $4K | |
| 0171 | Inj, epinephrine (belcher) | <1% | 24 | $4K |
| E0114 | Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips | <1% | 76 | $3K |
| 30140 | <1% | 13 | $3K | |
| 1159F | <1% | 11,968 | $3K | |
| 82803 | <1% | 247 | $3K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 62 | $3K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 106 | $3K |
| 99443 | <1% | 80 | $3K | |
| A4217 | Sterile water/saline, 500 ml | <1% | 133 | $3K |
| 92567 | <1% | 141 | $3K | |
| 86923 | <1% | 116 | $3K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $3K |
| 0430 | <1% | 110 | $3K | |
| 0257 | <1% | 535 | $3K | |
| Z4310 | <1% | 235 | $3K | |
| 77080 | <1% | 195 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 359 | $3K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 425 | $3K |
| X4301 | <1% | 27 | $3K | |
| X4300 | <1% | 27 | $3K | |
| 87205 | <1% | 561 | $3K | |
| 0324 | <1% | 1,588 | $2K | |
| 93975 | <1% | 13 | $2K | |
| 75574 | <1% | 14 | $2K | |
| 82947 | <1% | 1,128 | $2K | |
| 82140 | <1% | 252 | $2K | |
| 0011A | <1% | 56 | $2K | |
| 77263 | <1% | 13 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 174 | $2K |
| 74019 | <1% | 114 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 318 | $2K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 46 | $2K |
| 73060 | <1% | 128 | $2K | |
| Z4302 | <1% | 159 | $2K | |
| 76536 | <1% | 64 | $2K | |
| 72070 | <1% | 94 | $2K | |
| 88311 | <1% | 167 | $2K | |
| 87210 | <1% | 479 | $2K | |
| 92610 | <1% | 66 | $2K | |
| 73620 | <1% | 150 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 180 | $2K |
| 73552 | <1% | 73 | $2K | |
| 99156 | <1% | 31 | $2K | |
| 82728 | <1% | 280 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 212 | $1K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 14 | $1K |
| 80074 | <1% | 42 | $1K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 302 | $1K |
| 0305 | <1% | 3,208 | $1K | |
| 73700 | <1% | 13 | $1K | |
| 82607 | <1% | 285 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 62 | $1K |
| 0306 | <1% | 2,474 | $1K | |
| 0012A | <1% | 31 | $1K | |
| 86780 | <1% | 200 | $1K | |
| 77300 | <1% | 21 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 90 | $1K |
| 82746 | <1% | 123 | $1K | |
| 11046 | <1% | 25 | $976.87 | |
| 72050 | <1% | 63 | $972.46 | |
| 82570 | <1% | 509 | $969.29 | |
| 0730 | <1% | 1,235 | $953.97 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 187 | $948.72 |
| 87071 | <1% | 152 | $941.92 | |
| 97166 | <1% | 24 | $938.65 | |
| 71020 | <1% | 42 | $911.39 | |
| 72128 | <1% | 12 | $883.83 | |
| 82248 | <1% | 177 | $877.23 | |
| 80305 | <1% | 102 | $871.11 | |
| 12002 | <1% | 99 | $851.92 | |
| 73070 | <1% | 73 | $848.26 | |
| 71010 | <1% | 62 | $826.40 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 135 | $825.05 |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $809.39 |
| 99307 | <1% | 57 | $775.69 | |
| 76818 | <1% | 85 | $759.85 | |
| 58558 | <1% | 12 | $756.00 | |
| 00812 | <1% | 17 | $713.25 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 232 | $677.06 |
| 86308 | <1% | 156 | $626.45 | |
| 84156 | <1% | 306 | $583.36 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 26 | $569.61 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 128 | $519.74 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 16 | $492.98 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 98 | $484.67 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 56 | $468.50 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 640 | $446.81 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 167 | $422.64 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 44 | $414.76 |
| 73660 | <1% | 41 | $403.67 | |
| 82043 | <1% | 394 | $401.15 | |
| C2629 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, laser | <1% | 103 | $380.00 |
| 30520 | <1% | 13 | $363.00 | |
| 29515 | <1% | 47 | $362.70 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 24 | $357.84 |
| 84550 | <1% | 232 | $334.75 | |
| 0307 | <1% | 1,687 | $320.16 | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 85 | $299.52 |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 20 | $288.88 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 28 | $263.37 |
| 0251 | <1% | 56 | $239.93 | |
| 85014 | <1% | 200 | $237.06 | |
| 83540 | <1% | 107 | $230.97 | |
| 3074F | <1% | 1,710 | $227.94 | |
| 3077F | <1% | 1,080 | $227.94 | |
| 3008F | <1% | 4,135 | $227.41 | |
| 94760 | <1% | 66 | $226.43 | |
| 0302 | <1% | 855 | $226.00 | |
| 84466 | <1% | 56 | $223.08 | |
| 51702 | <1% | 28 | $221.74 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 44 | $192.86 |
| 86800 | <1% | 13 | $173.95 | |
| 3075F | <1% | 695 | $173.37 | |
| 70360 | <1% | 15 | $158.93 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 40 | $157.60 |
| 86376 | <1% | 12 | $155.64 | |
| 73120 | <1% | 13 | $146.49 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 12 | $146.32 |
| 83615 | <1% | 30 | $137.04 | |
| 29130 | <1% | 24 | $108.05 | |
| 85018 | <1% | 81 | $103.05 | |
| 82150 | <1% | 25 | $86.70 | |
| 0320 | <1% | 119 | $81.60 | |
| 1160F | <1% | 2,884 | $75.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 75 | $71.02 |
| 3078F | <1% | 1,947 | $54.58 | |
| 88302 | <1% | 12 | $53.24 | |
| 85652 | <1% | 29 | $40.22 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 24 | $32.84 |
| 3079F | <1% | 1,077 | $29.70 | |
| 99001 | <1% | 938 | $28.76 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 38 | $27.42 |
| 84132 | <1% | 14 | $26.02 | |
| A0425 | Ground mileage, per statute mile | <1% | 467 | $24.18 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 12 | $22.98 |
| 83986 | <1% | 12 | $22.71 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 16 | $19.50 |
| 84295 | <1% | 12 | $16.86 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 32 | $15.98 |
| 99072 | <1% | 168 | $3.60 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 59 | $2.09 |
| 3080F | 0% | 345 | $0.00 | |
| 0410 | 0% | 176 | $0.00 | |
| 0310 | 0% | 26 | $0.00 | |
| 0720 | 0% | 25 | $0.00 | |
| 0350 | 0% | 52 | $0.00 | |
| A0999 | Unlisted ambulance service | 0% | 86 | $0.00 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 154 | $0.00 |
| 96376 | 0% | 24 | $0.00 | |
| 0255 | 0% | 47 | $0.00 | |
| 0721 | 0% | 62 | $0.00 | |
| 0352 | 0% | 25 | $0.00 | |
| 0409 | 0% | 14 | $0.00 | |
| 0460 | 0% | 203 | $0.00 | |
| 0402 | 0% | 343 | $0.00 | |
| 0489 | 0% | 110 | $0.00 | |
| S9999 | Sales tax | 0% | 86 | $0.00 |
| 96379 | 0% | 17 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRAFFOUL, JOHN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| White Memorial Medical Center | Los Angeles, CA | $870K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.